

AMENDMENTS TO THE CLAIMS

1. (currently amended) A method of treating uterine serous papillary carcinoma ~~that over-express HER-2/neu in an individual in need of such treatment~~, comprising the step of administering to an ~~said~~ individual with said carcinoma a therapeutically effective dose of a humanized anti-HER-2/neu antibody that binds to the p185 extracellular domain of HER-2/neu.

2. (currently amended) The method of claim 1, wherein said antibody is the humanized murine anti-HER-2/neu monoclonal antibody 4D5 ~~a monoclonal antibody~~.

3-4. (canceled)

5. (currently amended) The method of claim 1 ~~[[4]]~~, wherein said antibody is administered to said individual in a dose of from about 4 mg/kg to about 8 mg/kg.

6. (withdrawn) The method of claim 1, further comprising the step of administering a therapeutically effective dose of interleukin-2 to said individual.

7. (withdrawn) The method of claim 6, wherein said interleukin-2 is recombinant interleukin-2.

8. (withdrawn) The method of claim 6, wherein said dose of interleukin-2 is non-toxic.

9. (withdrawn) The method of claim 6, wherein said interleukin-2 is administered to said individual in a dose of from about 1×10^6 IU/M² to about 10×10^6 IU/M².

10. (withdrawn) A method of differentiating primary uterine serous papillary carcinoma from serous papillary ovarian tumors in an individual, comprising the step of measuring the expression of HER-2/neu in said tissue, wherein the presence of an increased and constitutive expression pattern in said tissue indicates that said tumor is a uterine serous papillary carcinoma.

11. (withdrawn) A method of treating uterine serous papillary carcinoma in an individual in need of such treatment, comprising the step of administering to said individual a therapeutically effective dose of a HER-2/neu antibody and a therapeutically effective dose of interleukin-2.

12. (withdrawn) The method of claim 11, wherein said antibody is a monoclonal antibody.

13. (withdrawn) The method of claim 12, wherein said antibody is a humanized monoclonal antibody.

14. (withdrawn) The method of claim 13, wherein said antibody is Herceptin®.

15. (withdrawn) The method of claim 14, wherein said antibody is administered to said individual in a dose of from about 4 mg/kg to about 8 mg/kg.

16. (withdrawn) The method of claim 11, wherein said interleukin-2 is recombinant interleukin-2.

17. (withdrawn) The method of claim 11, wherein said dose of interleukin-2 is non-toxic.

18. (withdrawn) The method of claim 11, wherein said interleukin-2 is administered to said individual in a dose of from 1×10^6 IU/M² to about 10×10^6 IU/M².